Palvella Therapeutics
Rare disease biopharmaceutical company.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | $78.9m | Post IPO Equity | |
| Total Funding | 000k | ||
Ligand Pharmaceuticals(exited)
CAM Capital(exited)
Samsara BioCapital(exited)
BVF Partners(exited)
Agent Capital(exited)
BioAdvance(exited)
Nolan Capital(exited)
13 Ventures(exited)
Gore Range Capital(exited)
Petrichor(exited)
Eric Stone(exited)
Opaleye Management(exited)
Adams Street Partners(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Palvella Therapeutics
Edit
ACQUISITION by Palvella Therapeutics Jul 2024